Multi-omics characterization of immune responses in cancer
Identyfikator grantu: PT01120
Kierownik projektu: Victor Urbiola-Salvador
Międzyuczelniany Wydział Biotechnologii UG i GUMed
Gdańsk
Data otwarcia: 2024-02-20
Streszczenie projektu
Cancer is one of the most common leading death causes worldwide. Despite the great advances in cancer research and treatment such as recent immunotherapies, a majority of patients exhibit low responses due to the influence of other non-targeted inflammatory/immunosuppressive mechanisms. T-cells play an essential role in cancer and inflammatory diseases.
Therefore, deep understanding of the pathogenic molecular mechanisms of cancer and immune responses is urgently needed. Advances in multi-omics technologies are revolutionizing cancer research including genomics, transcriptomics, and proteomics among others.
This project aims to perform multi-omics data analysis to characterize the underlying immune responses in cancer. We will implement state-of-the-art bioinformatics pipelines and software for biological big data analysis as well as the implementation of different deep machine learning algorithms and neural networks. We speculate that the research will facilitate biomarkers discovery as well as identification of novel regulators of T-cell-driven immune responses. These novel regulators may be potential immunotherapy targets for cancer treatment.
Therefore, deep understanding of the pathogenic molecular mechanisms of cancer and immune responses is urgently needed. Advances in multi-omics technologies are revolutionizing cancer research including genomics, transcriptomics, and proteomics among others.
This project aims to perform multi-omics data analysis to characterize the underlying immune responses in cancer. We will implement state-of-the-art bioinformatics pipelines and software for biological big data analysis as well as the implementation of different deep machine learning algorithms and neural networks. We speculate that the research will facilitate biomarkers discovery as well as identification of novel regulators of T-cell-driven immune responses. These novel regulators may be potential immunotherapy targets for cancer treatment.